(S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-氨基丙酸乙酯 | 369648-61-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-氨基丙酸乙酯
• 英文名称: ethyl-(2S)-2-amino-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate
• 英文别名: (S)-ethyl 3-(4-(2,7-naphthyridin-1-ylamino)phenyl)-2-aminopropanoate；ethyl (2S)-2-amino-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate
• CAS: 369648-61-3
• 化学式: C₁₉H₂₀N₄O₂
• 分子量: 336.393
• InChiKey: GBULTAVXJRJYDK-KRWDZBQOSA-N

物化性质

• 沸点：
  512.7±50.0 °C(Predicted)
• 密度：
  1.265±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  90.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-keto-3-hydroxyspiro[3,5]-non-2-ene 、 (S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-氨基丙酸乙酯 以 二氯甲烷 为溶剂， 反应 24.0h， 以73%的产率得到(S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-((3-氧代螺[3.5]壬-1
  参考文献：
  名称：

  [EN] PHENYLALANINE ENAMIDE DERIVATIVES
  [FR] DERIVES DE PHENYLALANINE ENAMIDE

  摘要：

  公式（1）中描述了苯丙氨酸烯酰胺衍生物，其中R1为-CH(CH3)2，-(CH2)2CH3；-CH2C(CH3)3，-CH2CH2OH，-CH2CH2OCH3，-CH2CH2OCH2CH2OH，-CH2CH2OCH2CH2OCH3，公式（A）基团；以及它们的盐、溶剂合物和N-氧化物。根据本发明的化合物是α4整合素的有效和选择性抑制剂。这些化合物可用于调节细胞粘附，特别是可用于预防和治疗包括白细胞外渗在内的炎症等疾病或紊乱，本发明还涉及这种用途以及用于制造用于治疗此类疾病或紊乱的药物的化合物的用途。

  公开号：

  WO2004007494A1
• 作为产物：
  描述：

  (S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-((叔丁氧基羰基)氨基)丙酸乙 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (S)-3-(4-((2,7-萘啶-1-基)氨基)苯基)-2-氨基丙酸乙酯
  参考文献：
  名称：

  [EN] PHENYLALANINE ENAMIDE DERIVATIVES
  [FR] DERIVES DE PHENYLALANINE ENAMIDE

  摘要：

  公式（1）中描述了苯丙氨酸烯酰胺衍生物，其中R1为-CH(CH3)2，-(CH2)2CH3；-CH2C(CH3)3，-CH2CH2OH，-CH2CH2OCH3，-CH2CH2OCH2CH2OH，-CH2CH2OCH2CH2OCH3，公式（A）基团；以及它们的盐、溶剂合物和N-氧化物。根据本发明的化合物是α4整合素的有效和选择性抑制剂。这些化合物可用于调节细胞粘附，特别是可用于预防和治疗包括白细胞外渗在内的炎症等疾病或紊乱，本发明还涉及这种用途以及用于制造用于治疗此类疾病或紊乱的药物的化合物的用途。

  公开号：

  WO2004007494A1

文献信息

• Phenylalanine enamide derivatives
  申请人：——

  公开号：US20020169336A1

  公开（公告）日：2002-11-14

  Phenylalanine enamide derivatives of formula (1) are described: 1 wherein R 1 is a group Ar 1 L 2 Ar 2 Alk- in which: Ar 1 is an optionally substituted aromatic or heteroaromatic group; L 2 is a covalent bond or a linker atom or group; Ar 2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH 2 —CH(R)13 , —CH═C(R)— or 2 in which R is a carboxylic acid (—CO 2 H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R 2 )— group in which: R x , R y and R z which may be the same or different is each a hydrogen atom or an optional substituent; or R z is an atom or group as previously defined and R x and R y are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.

  描述了公式（1）的苯丙氨酰烯衍生物：1其中R1是一个Ar1L2Ar2Alk-基团，其中：Ar1是一个可选择的取代芳香族或杂芳族基团；L2是一个共价键或连接原子或基团；Ar2是一个可选择的取代芳亚烷基团或杂芳亚烷基团；Alk是一个链-CH2-CH（R）13，-CH═C（R）-或2，其中R是一个羧酸（-CO2H）或其衍生物或生物体的立体异构体；X是一个-O-或-S-原子或-N（R2）-基团，其中：Rx，Ry和Rz可以相同或不同，每个是氢原子或可选择的取代基团；或Rz是先前定义的原子或基团，Rx和Ry连接在一起形成一个可选择的取代螺环脂肪族或杂环脂肪族基团；以及其盐，溶剂化合物，水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合，并可用于预防和治疗免疫或炎症性疾病或涉及细胞不适当生长或迁移的疾病。
• 2, 7-naphthyridine derivatives
  申请人：——

  公开号：US20020115684A1

  公开（公告）日：2002-08-22

  2,7-Naphthyridine containing squaric acids of formula (1) are described: 1 wherein Ar 1 is an optionally substituted 2,7-naphthridin-1-yl group; L 2 is a covalent bond or a linker atom or group; Ar 2 is an optionally substituted aromatic or heteroaromatic chain; Alk is a chain —CH 2 CH(R)—, —CH═C(R)—, 2 in which R is a carboxylic acid (—CO 2 H) or a derivative or biostere thereof; R 1 is a hydrogen atom or a C 1-6 alkyl group; L 1 is a covalent bond or a linker atom or group; Alk 1 is an optionally substituted aliphatic chain; n is zero or the integer 1; R 2 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloalphatic, heteropoly-cycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.

  描述了公式（1）中含有2,7-萘啶基丙二酸的化合物：其中，Ar1是可选取代的2,7-萘啶-1-基基团；L2是共价键或连接原子或基团；Ar2是可选取代的芳香或杂芳链；Alk是链-CH2CH（R）-，-CH═C（R）-，其中R是羧酸（-CO2H）或其衍生物或生物立体异构体；R1是氢原子或C1-6烷基基团；L1是共价键或连接原子或基团；Alk1是可选取代的脂肪链；n为零或整数1；R2是氢原子或可选取代的杂脂肪、环脂肪、杂环脂肪、多环脂肪、杂多环脂肪、芳香或杂芳基团；以及它们的盐、溶剂合物、水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合，并可用于预防和治疗免疫或炎症性疾病或涉及细胞不适当生长或迁移的疾病。
• Enamine derivatives
  申请人：Celltech R & D Limited

  公开号：US06780874B2

  公开（公告）日：2004-08-24

  Enamine derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in, which Ar1 is an aromatic or heteroaromatic group, L2 is a covalent bond or a linker atom or group, Ar2 is an arylene or heteroarylene group and Alk is a chain —CH2—CH(R)—, —CH═C(R)— or in which R is a carboxylic acid or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; Cy is a cycloaliphatic or heterocycloaliphatic ring in which X is a N atom or a C(Rw) group; Rx is a oxo, thioxo, or imino group; Rw and Rz is each a hydrogen atom or optional substituent; provided that Cy is not a cyclobutenedione group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.

  描述了公式（1）的恩氏衍生物：其中R1是Ar1L2Ar2Alk-基团，其中Ar1是芳香族或杂芳族基团，L2是共价键或连接原子或基团，Ar2是芳烃或杂芳烃基团，Alk是链-CH2-CH（R）-，-CH═C（R）-或其中R是羧酸或其衍生物或生物立体异构体；R2是氢原子或C1-6烷基基团；Cy是环状脂肪族或杂环状脂肪族环，其中X是N原子或C（Rw）基团；Rx是氧代、硫代或亚氨基基团；Rw和Rz分别是氢原子或可选取代基；前提是Cy不是环丁二酮基团；以及其盐、溶剂化合物、水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合，并可用于预防和治疗免疫或炎症性疾病，或涉及细胞不适当生长或迁移的疾病。
• Phenylalanine Enamide Derivatives
  申请人：Brand Stephen

  公开号：US20070167483A1

  公开（公告）日：2007-07-19

  Phenylalanine enamide derivatives of formula (1) are described: wherein R 1 is a group Ar 1 L 2 Ar 2 Alk- in which: Ar 1 is an optionally substituted aromatic or heteroaromatic group; L 2 is a covalent bond or a linker atom or group; Ar 2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain in which R is a carboxylic acid (—CO 2 H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R 2 )— group in which: R x , R y and R z which may be the same or different is each a hydrogen atom or an optional substituent; or R z is an atom or group as previously defined and R x and R y are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.

  描述了公式（1）的苯丙氨酸烯酰衍生物：其中R1是Ar1L2Ar2Alk-基团，其中：Ar1是可选的取代芳香族或杂芳族基团；L2是共价键或连接原子或基团；Ar2是可选的取代芳烃或杂芳烃基团；Alk是链，在其中R是羧酸（-CO2H）或其衍生物或生物同分异构体；X是一个-O-或-S-原子或-N（R2）-基团，其中：Rx，Ry和Rz可相同或不同，分别是氢原子或可选的取代基团；或Rz是先前定义的原子或基团，而Rx和Ry结合在一起形成可选的取代螺环脂肪族或杂环脂肪族基团；以及其盐，溶剂化合物，水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合，并用于预防和治疗免疫或炎症性疾病或涉及细胞不适当生长或迁移的疾病。
• 2,7-naphthyridine derivatives
  申请人：Celltech R&D Limited

  公开号：US06545013B2

  公开（公告）日：2003-04-08

  2,7-Naphthyridine containing squaric acids of formula (1) are described: wherein Ar1 is an optionally substituted 2,7-naphthridin-1-yl group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted aromatic or heteroaromatic chain; Alk is a chain —CH2CH(R)—, —CH═C(R)—,  in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; R1 is a hydrogen atom or a C1-6alkyl group; L1 is a covalent bond or a linker atom or group; Alk1 is an optionally substituted aliphatic chain; n is zero or the integer 1; R2 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloalphatic, heteropoly-cycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.

  本文描述了公式（1）中含有2,7-萘啶基丙烯酸的化合物：其中Ar1是可选取代的2,7-萘啶-1-基基团；L2是共价键或连接原子或基团；Ar2是可选取代的芳香或杂环芳香链；Alk是链-CH2CH（R）-，-CH═C（R）-，其中R是羧酸（-CO2H）或其衍生物或生物立体异构体；R1是氢原子或C1-6烷基基团；L1是共价键或连接原子或基团；Alk1是可选取代的脂肪链；n为零或整数1；R2是氢原子或可选取代的杂原子脂肪、环状脂肪、杂环状脂肪、多环芳烃、杂多环芳烃、芳香或杂环芳香基团；以及它们的盐、溶剂化合物、水合物和N-氧化物。这些化合物能够抑制整合素与其配体的结合，并用于预防和治疗免疫或炎症性疾病或涉及细胞不适当生长或迁移的疾病。